Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity
Chien-Chun Steven Pai, … , Gillian Kingsbury, Lawrence Fong
Chien-Chun Steven Pai, … , Gillian Kingsbury, Lawrence Fong
Published December 10, 2018
Citation Information: J Clin Invest. 2019;129(1):349-363. https://doi.org/10.1172/JCI123391.
View: Text | PDF
Research Article Immunology Oncology

Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity

Abstract

While immune checkpoint blockade leads to potent antitumor efficacy, it also leads to immune-related adverse events in cancer patients. These toxicities stem from systemic immune activation resulting in inflammation of multiple organs, including the gastrointestinal tract, lung, and endocrine organs. We developed a dual variable domain immunoglobulin of anti-CTLA4 antibody (anti-CTLA4 DVD, where CTLA4 is defined as cytotoxic T lymphocyte–associated antigen-4) possessing an outer tumor-specific antigen-binding site engineered to shield the inner anti-CTLA4–binding domain. Upon reaching the tumor, the outer domain was cleaved by membrane type-serine protease 1 (MT-SP1) present in the tumor microenvironment, leading to enhanced localization of CTLA4 blockade. Anti-CTLA4 DVD markedly reduced multiorgan immune toxicity by preserving tissue-resident Tregs in Rag 1–/– mice that received naive donor CD4+ T cells from WT C57BL/6j mice. Moreover, anti-CTLA4 DVD induced potent antitumor effects by decreasing tumor-infiltrating Tregs and increasing the infiltration of antigen-specific CD8+ T lymphocytes in TRAMP-C2–bearing C57BL/6j mice. Treg depletion was mediated through the antibody-dependent cellular cytotoxicity (ADCC) mechanism, as anti-CTLA4 without the FcγR-binding portion (anti-CTLA4 DANA) spared Tregs, preventing treatment-induced toxicities. In summary, our results demonstrate an approach to anti-CTLA4 blockade that depletes tumor-infiltrating, but not tissue-resident, Tregs, preserving antitumor effects while minimizing toxicity. Thus, our tumor-conditional anti-CTLA4 DVD provides an avenue for uncoupling antitumor efficacy from immunotherapy-induced toxicities.

Authors

Chien-Chun Steven Pai, Donald M. Simons, Xiaoqing Lu, Michael Evans, Junnian Wei, Yung-hua Wang, Mingyi Chen, John Huang, Chanhyuk Park, Anthony Chang, Jiaxi Wang, Susan Westmoreland, Christine Beam, Dave Banach, Diana Bowley, Feng Dong, Jane Seagal, Wendy Ritacco, Paul L. Richardson, Soumya Mitra, Grace Lynch, Pete Bousquet, John Mankovich, Gillian Kingsbury, Lawrence Fong

×

Figure 1

Anti-CTLA4–mediated immune-related toxicities in a murine model.

Options: View larger image (or click on image) Download as PowerPoint
Anti-CTLA4–mediated immune-related toxicities in a murine model. Eight- ...
Eight- to ten-week-old male Rag 1–/– mice (on C57BL/6j background) were adoptively transferred with purified CD4+CD25–CD45RBhi cells from WT mice. (A) Sorting strategy. (B) Body weight loss over time after treatment. (C) Different organs were harvested at day 45, and pathological changes were examined using H&E staining under a microscope. Arrows indicate lymphocytic infiltration and pathological changes. (D–F) Target organ pathological scores were evaluated by a board-certified pathologist in a single-blind fashion. (G) Splenocytes were harvested at day 45 from different treatment groups, and CD4+ T cells were examined for TNF-α secretion by flow cytometry. (H) Percentage of TNF-α+CD4+ T cells among CD45+ cells. Experiments were conducted twice, and data were shown with 5 mice per group. Three mice from the Rag1–/– only group were used as negative control. For the TNF-α experiment, data were collected from 3 mice per group. Bars represent mean ± SEM. *P < 0.05; **P < 0.01; ****P < 0.0001, 1-way ANOVA or 2-way ANOVA with post hoc Tukey’s test.